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Part 2
Introduction and meeting objectives
In all societies, the burden and cost of allergic and chronic 
respiratory diseases are increasing rapidly. Most economies 
are struggling to deliver modern health care effectively. 
There is a need to support the transformation of the health 
care system into integrated care with organizational health 
literacy. MASK (Mobile Airways Sentinel NetworK) (1), 
a new development of the ARIA (Allergic Rhinitis and its 
Impact on Asthma) initiative (2), and POLLAR (Impact of 
Air POLLution on Asthma and Rhinitis, EIT Health) (3), 
in collaboration with professional and patient organizations 
in the field of allergy and airway diseases, are proposing 
real-life ICPs—centred around the patient with rhinitis and 
using mHealth monitoring of environmental exposure. 
An expert meeting took place at the Pasteur Institute 
in Paris, December 3, 2018. The aim was to discuss next-
generation care pathways following an ongoing political 
agenda (4,5): (I) patient participation, health literacy and 
self-care through technology-assisted “patient activation”; 
(II) implementation of care pathways by pharmacists 
and (III) Next-generation guidelines assessing the 
recommendations of GRADE guidelines in rhinitis and 
asthma using real-world evidence (RWE) assessed by 
mobile technology. 
The present document reviews the workshop report and 
follows on from Part 1. 
Self-management strategies
Self-management
Self-management may be defined as: “… the tasks that 
individuals must undertake to live well with chronic conditions. 
These tasks include having the confidence to deal with the medical 
management, role management and emotional management 
of their conditions” (6). Self-management support is the 
assistance provided by professional/informal caregivers to 
enable patients to confidently make decisions and manage 
disease and health-related tasks (7). 
The implementation of supported self-management 
requires patients, professionals and organisations to change 
behaviour, practice or routines. Behavioural change models, 
such as COM-B (Capacity, Opportunity, Motivation 
- Behaviour) (8), offer frameworks for considering 
implementation strategies, potentially supported by 
technology. 
 People with long-term conditions are, de facto, 
managing their condition almost all of the time. 
Professional support aims to empower them to 
‘self-manage’ better. Understanding an individual’s 
beliefs ,  his/her demographic,  cultural  and 
healthcare context, as well as the barriers (such as 
limited health literacy, poor access to resources) 
enables an assessment of capacity. Asthma/
rhinitis is often a low priority; engaging with self-
management support to achieve personal goals may 
enhance motivation. Technology can conveniently 
provide reminders, detect triggers, (silently) 
monitor conditions, provide action plans, keep 
appointment diaries, facilitate remote consultations 
and enable peer-to-peer support.
 Professionals’ existing techniques (such as ‘safety-
netting’ consultations, providing information) 
form a basis on which to build the skills of patient-
centred consultations (shared decision-making; 
health coaching), so that asthma/rhinitis supported 
self-management becomes a normal approach to 
care. Training needs to motivate (by highlighting 
benefits to patients and their own professional 
development) and address individual learning needs 
(limited experience, de-skilling). Technology can 
offer computerised decision support and provide 
on-line learning. 
 Organisational routines and local/national healthcare 
policies can provide opportunities for change but 
can also stifle innovation. Effective implementation 
involves tailoring to local capacity, addressing 
practical barriers, promoting prioritisation of 
asthma/rhinitis and supported self-management, 
and reinforcing change. Technology can improve 
the sharing of (and learning from) data as well as 
inter-professional communication. It can also help 
to monitor innovation. 
Technological approaches developed with patient/
professional stakeholders can underpin many components of 
supported self-management (9). Self-management ‘apps’ are 
typically multifaceted, incorporating monitoring of disease 
status, managing pharmacotherapy, improving adherence, 
providing reminders, linking to information, and supporting 
lifestyle changes (10). Consideration of Behavioural change 
theory (such as COM-B) and practical taxonomies (for 
example PRISMS) suggests that telehealth could potentially 
contribute to a broader range of support strategies (11). 
The self-management group are developing a 4-page 
pocket guide on supported self-management (including 
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the use of mobile technology) in the context of the rhinitis 
integrated care pathway. More widely, they will provide 
innovative approaches to dissemination.
Systemic changes needed for self-management
Well-developed healthcare cultures and empowered 
individuals already use self-management as a beacon and 
tradition. But overall equity and sustainability of our 
healthcare and societal model (12) require that we strive 
towards a nurturing process that extends practices of self-
care and self-management to all, making self-management 
the norm rather than the exception.
We therefore point to four areas of systemic change that 
are needed to benefit this process.
Health literacy
We need to recognize that improved health literacy is the 
result of strategic adaptations—not just of information 
material, but also of our educational system (13). We also 
need to help all citizens to understand symptoms and labels, 
and empower them for a lifetime of curious and considerate 
energy to link their natural perseverance with the quality 
of life they want. Concretely, this would require the school 
curriculum to teach “prevention” and to slightly shift the 
teaching of biology, food science, social science, etc. towards 
a user-need perspective (14).
Labour market
Most of us spend at least a third of our adult life in the 
labour market. Naturally our actions and conditions in 
the work place have a significant impact on our health 
and productivity. Instead of simply considering health 
promotion in the workplace as a benefit for the employee, 
both management and research should be shifted towards 
a holistic productivity perspective (15). Put simply, 
supporting better health and self-management in employees 
is obviously good for profits. At system level, it is also 
obviously as good as SOP in every company, as deficiencies 
are bad for company profits, bad for national economies, 
and bad for the health and wellbeing of citizens (16). But 
let co-creation & incentivization be the primary tool, not 
simply legislative command & control.
Research
Studying self-management and developing new methods 
(physical, digital, structures) of support require a wider 
perspective than that of natural science only. To study health 
and wellbeing, fields like sociology (17), anthropology, 
psychology, communication, and law should be included. 
There should be more emphasis on interdisciplinary 
research (18) involving support for emerging practices, as 
this type of prevention is rarely studied and documented.
Policy
Efforts towards sustainability in European policies have 
shown how joint goals have significant impact, even years 
before they can be realized. The same is true for self-
management. We should realize that to solve certain 
challenges and reach certain goals in self-management, our 
policies need to first support these changes (19). Integrating 
self-management into policy means looking not only at 
health policies, but also at social, development, educational, 
research, employment and economic policies (9). If we do 
so, we can lessen the health inequality, reduce strains on 
traditional healthcare and ensure an empowering system of 
change that promotes self-management (20).
Personalised care—supporting self management
There is no universally-agreed definition for personalised 
care. NHS England defines personalised care as “people 
having choice and control over the way their care is planned 
and delivered”. It is based on ‘what matters’ to them and 
their individual strengths and needs (21). Personalised care 
is people having choice and control over decisions that 
affect their own health and wellbeing within a system that 
harnesses the expertise, capacity and potential of people, 
families and communities in delivering better outcomes and 
reducing health inequalities. 
In relation to long-term conditions, this means ensuring 
that people with long-term physical and mental health 
conditions have the support to build knowledge, skills and 
confidence to enable them to make informed choices about 
treatments and to be able to effectively manage their health 
condition on a day-to-day basis.
Patients with low health literacy should be proactively 
identified and support should be tailored and targeted in a 
way that is appropriate for the patient and that takes into 
account their capability, opportunity and motivation to 
proactively [COM-B model (8)] manage their health.
Evidence-based types of support may include structured 
self-management education, health coaching and peer 
support. New behaviours may then be reinforced and 
supported daily through Apps and mobile technology.
The integrated care vision of the practicing allergist
Allergists have multiple complex tasks to perform for their 
patients: they must make clinical diagnoses, perform allergic 
tests, establish a relationship between the results and the 
clinical history of the patient. They have to determine the 
allergic or non-allergic features as well as the non-specific 
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hyperactivity of the clinical signs (22-24).
They also have to explore all cofactors of the allergy, the 
multimorbidities and their entire environment (25).
They must also implement a therapeutic strategy: 
symptomatic treatment adapted to the lifestyle of the 
patient, to his/her personality and to his/her desires.
A relationship of trust should be established rapidly—key 
to the success of a treatment and a long-term follow-up is 
required for chronic disease.
Allergic rhinitis is a complex disease that results from 
interactions between multiple genetic and environmental 
factors (the exposome). Indoor and outdoor aeroallergens 
and air pollutants therefore play a key role in the 
etiopathogenesis of the inflammatory response to allergens 
and in the clinical manifestations of allergic rhinitis. The 
allergist may have to help the patient find other allergens, 
hidden moulds, tobacco smoke, ubiquitous domestic 
pollutants, sources of volatile/semi-volatile organic 
compounds (VOCs/SVOCs) (26,27). 
The practitioner must deal with all the epithelial 
barriers of the patient: cutaneous (eczema), digestive (food 
allergies), eyes, ENT and bronchial (asthma) and needs to 
determine the therapeutic priorities. Management of the 
patient’s stressors is essential for a successful treatment and 
understanding of the patient’s allergy history (28).
The intervention of new technologies will revolutionize 
the care of the patients: analysis of the indoor environment, 
establishment of a timeline, follow-up of treatment, 
allergenic desensitization, therapeutic education. For 
example, preparation of the next visit, which will consist 
of reviewing the symptoms that have occurred in the 
meantime, can be facilitated by the collection of events 
on the smartphone. This tool may help the allergist to 
understand the patient and his/her behaviour (1).
ARIA in the pharmacy 
The paradigm of how we manage chronic diseases is 
shifting with a growing understanding that this is a complex 
process, requiring a coordinated effort from healthcare 
providers and patients. Pharmacists are key members of 
these integrated care pathways (ICPs) resolving medication-
related problems, optimizing regimens, improving 
adherence and recommending therapies while establishing 
liaisons between patients and physicians (2).
More than 15 years after the seminal “ARIA in the 
Pharmacy” paper (29), much has changed in community 
pharmacy and allergic rhinitis (AR) management (30,31). Our 
aim for the session was to develop a Pocket Guide (PG) to 
be used by pharmacists in the management of AR. This PG 
provides a clinical guide for pharmacists which is consistent 
with latest evidence, updated AR guidelines for pharmacy (32) 
and ICPs as articulated in the latest ARIA AR guidelines. 
AR is a complex chronic condition and implementing 
guidelines for AR management in community pharmacy 
is particularly important, as most patients do not consult 
a medical practitioner when selecting medication for their 
AR. The pharmacist’s role must therefore encompass a 
broad range of management issues including confirming 
the presence of AR, treatment selection, patient self-
management, long-term monitoring and patient support.
With the high level of self-diagnosis, the ability of 
pharmacists to recognise AR is critical. The proposed PG 
includes an 8-item questionnaire to assist the pharmacist 
and subsequently a flowchart to match the diagnosis to 
appropriate and optimal treatment for AR. Guidelines 
consider a range of medications that can be used in the 
treatment of AR based on symptom severity and duration. 
Considering non-prescribed medications, intra nasal 
corticosteroids (INCS) are the most effective treatment for 
AR, especially in patients with co-existing asthma. Pricing, 
cultural barriers, specific country regulations, availability, 
and even patients’ preference for oral vs nasal treatment 
all mean that INCS may not necessarily be available or 
the most desirable treatment for all patients. Therefore, 
a broader understanding of local context was taken into 
consideration when recommending treatment. 
AR control should be considered as the most important 
endpoint, as it represents a measure of the efficacy of the 
prescribed treatment and of the patient’s quality of life. In this 
regard, the proposed flowchart uses Visual Analogue Scales 
(VASs) to assist pharmacists in determining the optimal non-
prescribed medication to recommend. The MASK-air app 
is proposed for AR monitoring, as this tool appears to be 
appropriate for most patients and enables patient follow-up (33). 
The working group members believe that the integration 
and shared responsibility of all the stakeholders proposed 
in a common ICP can (I) improve AR outcome, (II) ensure 
appropriate, safe and cost-effective medication use, and 
(III) lower the health care utilisation rate through a more 
appropriate and timely utilisation of health care services. 
Next-generation guidelines
Background
Guidelines are recommendations intended to assist providers 
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and recipients of health care and other stakeholders in 
making informed decisions. However, single guideline 
recommendations often require context and integration in 
care pathways. This is because patients’ problems are often 
complex and require stepwise, pathway driven approaches 
to patient care. In turn, this creates problems about the 
certainty of the evidence in decisions because such decisions 
should be supported by unbiased evidence. 
The methodology for the integration or development 
of recommendations from pathways is not well defined. 
Piecing individual recommendations together will often 
lead to low or very low certainty evidence in the pathway 
because of missing information for evidence that links 
steps in a pathway together. This requires rethinking both 
guideline development and study design. 
For instance, the 2016 ARIA guidelines included the 
following two recommendations (Table 1).
How can such recommendations be integrated? To 
achieve this, we require study designs that can test the 
combinations of such recommendations and achieve 
high certainty in pathways. According to the Grading 
of Recommendations Assessment, Development and 
Evaluation (GRADE) approach (35,36), high certainty 
requires that evidence is at low risk of bias, applicable, 
consistent (across studies), sufficiently precise and free from 
publication bias.
For example, we require studies that evaluate pathways 
such as those described in figure 1 to achieve this high 
certainty of evidence (Figure 1).
We believe that new technology—mHealth (37)—
can help with achieving this goal. Randomized trials that 
provide direct data on care pathways compared to usual 
care are doable and will help to achieve high certainty in 
the evidence. Such care will explore linked evidence directly 
compared to alternative strategies. Furthermore, they can 
provide widely applicable evidence, often erroneously called 
“real-world evidence”.
Innovative designs for chronic disease implementation 
trials
Background
Guideline recommendations often address isolated 
questions: they frequently focus on a single disease or 
problem or are not considered in context of the many 
decisions that are made along the pathway of moving 
from a health care problem and question to addressing the 
problem. Care pathways try to address the multiple options 
and iterative changes in a patient’s status and problems. 
Guideline recommendations should support these iterative 
changes.
However, the key challenge is that available evidence, 
both randomized trials and non-randomized studies, does 
not usually address the complex pathways and typically 
addresses the isolated decision points in a pathway. For 
example, when medication x is not achieving symptom 
control, we add medication y, then we leave our x and add z. 
However, often, this is not the way that studies are designed. 
Accepting that properly developed pathways require 
evidence, our guidelines must start identifying the best 
available evidence to support the decisions. The evidence 
is typically indirect and leads to connecting the relevant 
decision points. Considering all of the evidence together, 
the pathway is likely to be supported by low certainty in its 
overall structure (decision points) and timing.
Approach
The next-generation guidelines, through the intelligent 
use of tools like ARIA-based apps, in which patients 
record symptoms and that provide advice at given time 
points to follow pathways, are a unique opportunity to 
implement ARIA recommendations and to evaluate them 
in pathways. Studies should be carried out with patients 
being randomized to integrated care pathways or to 
follow ARIA recommendations that are not presented as 
pathways. Such studies will provide information on the 
use of the recommendations and on the usefulness of the 
pathways. Through implementation of recommendations, 
we will be able to increase our certainty in the evidence by 
evaluating the entire pathway and measuring outcomes in 
direct population-based studies that measure what patients 
do as opposed to what clinicians prescribe (and patients do 
not do).
Purpose of the meeting
We will present suggestions for the design and use active 
group discussion to discuss how to use existing data 
to better design trials, in particular through the use of 
mobile apps. 
Table 1 ARIA 2016 recommendations (34)
Recommendation 3A: in patients with SAR, we suggest a 
combination of an INCS with an INAH rather than an INAH alone 
(conditional recommendation/low certainty of evidence)
Recommendation 5A: in patients with SAR, we suggest an INCS 
rather than an INAH (conditional recommendation/moderate 
certainty of evidence)
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Care pathways in allergen immunotherapy
Allergen immunotherapy (AIT) is a proven therapeutic 
option for the treatment of allergic rhinitis and/or asthma. 
Many guidelines or national practice guidelines have 
been produced but the evidence-based method varies, 
many are complex and none propose care pathways. This 
paper reviews care pathways for AIT using strict criteria 
and provides simple recommendations that can be used 
by all stakeholders including health care professionals. 
The decision to prescribe AIT for the patient should 
be individualized and based on the relevance of the 
allergens, the persistence of symptoms despite appropriate 
medications according to guidelines as well as on the 
availability of good-quality and efficacious extracts. 
Allergen extracts cannot be regarded as generics. 
Immunotherapy is selected by specialists for stratified 
patients. There are no currently available validated 
biomarkers that can predict AIT success. In adolescents 
and adults, AIT should be reserved for patients with 
moderate/severe rhinitis or for those with moderate 
asthma who, despite appropriate pharmacotherapy and 
adherence, continue to exhibit exacerbations that appear 
to be related to allergen exposure, except in some specific 
cases. Immunotherapy may be even more advantageous 
in patients with multimorbidity. In children, AIT may 
prevent asthma onset in patients with rhinitis. mHealth 
tools are promising for the stratification and follow-up of 
patients. 
Figure 1 Development of algorithms for allergic rhinitis. VAS, Visual Analogue Scale. 
Random ization
1st line 
(Anti H1 O/IN or INCS 
or LTRA or INCS + AZE
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C
ontrol
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Deployment of ICPs to other chronic respiratory diseases 
Integrated care pathways in asthma
Asthma is a chronic disease characterized by variable 
symptoms such as shortness of breath, chest tightness 
and cough, associated with chronic airway inflammation 
and bronchial hyperresponsiveness. Worldwide, more 
than 300 million people suffer from asthma and, in 2015, 
360,000 patients died due to this disease (38). There is 
thus a huge need for better treatment and management of 
asthma in order to alleviate symptoms and prevent asthma 
attacks (i.e. exacerbations) and mortality. The treatment 
of asthma encompasses non-pharmacologic approaches 
such as allergen avoidance (in allergic asthmatics), smoking 
cessation (in smoking asthmatics) and weight reduction (in 
obese patients) as well as pharmacologic treatments (39). 
Asthma drug treatments consist of (I) maintenance 
treatment with inhaled corticosteroids (ICS) with or 
without long-acting beta2-agonists (LABA), and (II) rapid-
acting reliever therapies used as needed [such as short-
acting beta2-agonists (SABA) or fixed combinations of 
ICS and formoterol 9ICS/form)]. Non-adherence to ICS, 
overuse of SABA and incorrect inhaler technique are 
important risk factors for lack of asthma control and life-
threatening asthma attacks (40,41).
In asthma, as in other non-communicable chronic 
diseases (NCDs), several different levels of care can 
be discerned: patient self-care, care by the pharmacist, 
(primary) care by general practitioners and allied health 
professionals, (secondary) care by respiratory physicians and 
other specialists, and, finally, acute care during emergency 
department visits and/or during hospital admissions (42). A 
smooth integration of asthma care between all these levels 
into integrated care pathways (ICPs) is crucial in order to 
optimize asthma management and to reduce its burden of 
disease. Since pharmacists have a frequent contact with 
asthma patients (when renewing their medications) and have 
access to previous drug dispensing data, they can play a key 
role in improving adherence to ICS-containing therapies 
(as maintenance and/or as reliever), in preventing regular 
use or abuse of SABA and in optimizing inhaler technique. 
Patients whose asthma is not well-controlled should be 
referred promptly to primary care—and, if needed, to 
secondary care—for proper (differential) diagnosis and 
management. Secure user-friendly digital platforms should 
facilitate the integration of the pharmacist dossier and the 
electronic medical records. Bidirectional e-communication 
and interaction between all levels of care is required to 
successfully implement integrated care pathways (ICPs) in 
asthma in real life.
Care pathways in chronic rhinosinusitis
Care pathways for CRS have been defined in the European 
position paper on rhinosinusitis and nasal polyps (43) and 
in a commissioning CRS guide funded by ENT-UK and 
the Royal College of Surgeons (44). Different algorithms 
have been developed for primary and secondary care and in 
secondary care for chronic rhinosinusitis with (CRSwNP) 
or without (CRSsNP) the presence of nasal polyps. 
Diagnosis of CRS is based on the presence of 2 or more 
symptoms of which one should be nasal obstruction or 
discoloured discharge with or without facial pain, headache 
or smell disturbance for ≥12 weeks (45). Care pathways are 
insufficiently described for patient self-management on the 
one hand and for recalcitrant disease on the other hand (4). 
Also, co-morbidities are rarely part of the integrated 
approach for CRS. Especially in relation to new treatment 
options with monoclonal antibodies, an integrated approach 
of upper and lower airways is crucial (46). 
Moreover, there is a need for continuous re-evaluation 
and optimization of existing care pathways to increase the 
level of disease control. Also in CRS, an online educational 
platform is needed to inform both patients and health care 
professionals about these issues (45). 
Deployment of ICPs to COPD 
Chronic Obstructive Pulmonary Disease (COPD) is the 
third leading cause of death globally. Its prevalence is likely 
to increase as populations live much longer. The most 
frequent risk factors for COPD are smoking tobacco and 
exposure to air pollution, either indoors or outdoors. The 
majority of individuals with COPD live in low- and middle-
income countries (LMIC) and have not been diagnosed (47). 
While much emphasis must be given to primary prevention, 
there is an urgent need to promote an earlier diagnosis 
and management in most countries. There is no cure 
for COPD. However, secondary preventive measures 
related to avoiding further damage by stopping smoking 
and/or reducing exposure to pollution, combined with 
measures to prevent respiratory infections, a healthy diet, 
physical activity and medication, can reduce symptoms 
and exacerbations, improve quality of life and increase 
survival (47). The use of a mobile phone App may help 
patients and health care professionals to control COPD, 
through integrated care pathways, by several means: 
(I) raising awareness on the condition; (II) performing 
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screening for symptoms of COPD among individuals at 
risk and suggesting that a doctor should be consulted and 
spirometry performed, when needed; (III) monitoring 
symptoms to inform treatment; (IV) early detection of 
exacerbations; (V) reminders for adherence to treatment; 
(VI) informing family doctors of exacerbations requiring 
visits to emergency rooms; (VII) guiding patients on 
self-management; (VIII) offering information on air 
pollution; (IX) collecting early information on trends 
of increasing symptoms and exacerbations, which may 
alert for preparedness of individuals and health systems. 
An adaptation of the Allergy Diary, an App developed 
for allergic rhinitis which has been deployed in over 
23 countries (30), may speed up the process of development 
and deployment. Solutions for common health problems in 
LMIC must be innovative to combine effectiveness and low 
cost (48). The use of the proposed App has the potential to 
support policies aiming to detect COPD earlier, to foster 
behaviour modification including adherence to treatment, 
to guide self-management and provide danger alerts (49). 
The likely synergy of these features may deliver efficiency 
into overloaded and troublesome health care systems (50). 
The paediatric approach 
AIT for respiratory allergy is currently used in children 
with persistent/unresponsive symptoms to treatment (51). 
Claims for long-term efficacy have been suggested for 
years (52). However, supporting evidence is weak and long-
term intervention studies in children are difficult and even 
unethical. Although the primary end point of the recent 
GAP trial was not met, secondary end points suggested a 
disease-modifying effect on the onset of asthma (53).
AIT is a paradigm for personalised medicine. It takes the 
multitude of sensitisation and multimorbidity profiles of 
different patients into account, both cross-sectionally and in 
relation to their natural history. Indirect yet robust evidence 
provides clues on patients that may provide more benefit: 
the severity of respiratory allergic disease is associated with 
its persistence (54). Epitope spreading and development of 
new sensitisations suggest benefit with early intervention. 
Effects on school performance and education (55) further 
support the need for maximisation of treatment at a time of 
developmental/career milestones.
In parallel, more studies are needed to characterise 
long-term effects. Such studies cannot be randomised and 
even less blinded. Therefore, observational approaches, 
such as registry research, need to be used (56). Criteria 
for the quality assessment of such approaches are already 
available and rapidly developing (Roche, Papadopoulos 
et al., in press).
In addition, there are opportunities for disease 
prevention that have not been adequately explored, such as 
primary prevention. Support for such studies needs to come 
from governmental organisations/public sources, in order 
to identify optimal cost-efficacy strategies.
Deployment to developing countries
Chronic respiratory diseases (CRDs) affect more than one 
billion people and everyone is exposed to risk factors (57). 
They are inter-related to infectious conditions, which 
often exacerbate CRDs or may cause them. Common 
colds are the most frequent trigger of asthma and COPD 
exacerbations, whereas various other respiratory infections, 
including RSV, tuberculosis and HIV, may induce CRD. 
Respiratory diseases are among the leading causes of 
death globally (47). At the other side of the spectrum, in 
primary health care (PHC), respiratory diseases are the 
most frequent cause of medical visits (58). The burden 
of these diseases is disproportionally higher in LMIC, 
where diagnosis and management may be late. The cost of 
health is increasing with longevity, novel technologies for 
diagnosis and treatments, and CRDs are associated with 
multimorbidity. Fragmented and/or specialized approaches 
to PHC are inefficient and costly. An integrated care 
pathway to CRD has been proposed as a way to change 
current management strategies (2).
The challenge of LMIC to offer good quality universal 
PHC demands innovative solutions. In this context, a 
change in current paradigms to take advantage of mobile 
communications technology and give patients a prominent 
role in their health care is an opportunity not to be missed. 
The model of the Allergy Diary, an App developed for 
rhinitis deployed in over 23 countries (30,59), may facilitate 
this. A pilot experience for a new App aimed at people 
at risk of COPD primed by large media campaigns for 
raising recognition is proposed to be undertaken in Turkey, 
Vietnam and Brazil by leaders of the Global Alliance against 
Chronic Respiratory Diseases (GARD)/WHO (60). The 
objectives of this COPD App plan are: (I) raise awareness 
of COPD and risk factors; (II) screen subjects at risk by a 
simple electronic questionnaire; (III) suggest that people 
with scores indicative of COPD see a doctor and perform 
spirometry; (IV) estimate the proportion of under diagnosis; 
(V) monitor symptoms to inform treatment; (VI) detect 
exacerbations early. Three steps are required for this plan 
to be rolled out: (I) invite GARD Country organizations, 
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including the Ministry of Health, to discuss (6 months); 
(II) search for local funding for the campaign (1 year); (III) 
define an action plan and roll it out, partnering with as 
many organizations as possible, including governmental 
organizations, associations of health care professionals, 
universities and the private sector (18 months). 
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